STOCK TITAN

Twist Bioscience (TWST) director Chess exercises 18,417 options and sells shares

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Twist Bioscience Corp director Robert Chess exercised options for 18,417 shares of common stock on August 7, 2026 at an exercise price of $11.89 per share and sold the same 18,417 shares at $110.89 per share. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. Following these transactions, an entity associated with Chess, the Chess 1997 Trust, held 42,528 shares of common stock indirectly, with Chess and his spouse serving as sole trustees and beneficiaries.

Positive

  • None.

Negative

  • None.
Insider CHESS ROBERT
Role Director
Sold 18,417 shs ($2.04M)
Approx. gross sale proceeds $2.04M
Approx. exercise cost $219K
Approx. pre-tax spread $1.82M
Type Security Shares Price Value
Exercise Stock Option (right to buy) F1, F3 18,417 $0.00 $0.00
Exercise Common Stock F1 18,417 $11.89 $219K
Sale Common Stock F1 18,417 $110.89 $2.04M
holding Common Stock F2 -- -- --
Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 21,084 shares (Direct); Common Stock — 42,528 shares (Indirect, By the Chess 1997 Trust)
Footnotes (3)
  1. F1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2026.
  2. F2. The Reporting Person and his spouse are the sole trustees and the sole beneficiaries of the Chess 1997 Trust.
  3. F3. The option is immediately exercisable. 10% of the shares subject to the option vested on September 13, 2018, 15% of the shares subject to the option vested on March 24, 2019, and 1/48th of the shares subject to the option vested on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
Options Exercised 18,417 shares Stock option for common stock exercised on August 7, 2026
Exercise Price $11.89 per share Exercise or conversion price of stock option
Shares Sold 18,417 shares Common stock sale on August 7, 2026 following option exercise
Sale Price $110.89 per share Per-share price for common stock sale
Indirect Holdings 42,528 shares Common stock held indirectly by the Chess 1997 Trust after transactions
Option Expiration September 13, 2028 Expiration date of the exercised stock option
10b5-1 Plan Adoption Date May 8, 2026 Date the Rule 10b5-1 trading plan was adopted
Rule 10b5-1 trading plan regulatory
"transactions were effected pursuant to a Rule 10b5-1 trading plan previously adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
indirect ownership financial
"total shares following transaction held indirect by the Chess 1997 Trust"
vesting financial
"shares subject to the option vested on each monthly anniversary thereafter"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Twist Bioscience (TWST) director Robert Chess report in this Form 4?

Robert Chess reported exercising options for 18,417 TWST shares at $11.89 and selling 18,417 shares at $110.89 on August 7, 2026, all under a Rule 10b5-1 trading plan.

How many Twist Bioscience (TWST) shares did Robert Chess sell and at what price?

Robert Chess sold 18,417 shares of Twist Bioscience common stock at a price of $110.89 per share on August 7, 2026, immediately after exercising options for the same number of shares.

What options did Robert Chess exercise in Twist Bioscience (TWST)?

He exercised a stock option for 18,417 shares of Twist Bioscience common stock at an exercise price of $11.89 per share. The option was immediately exercisable and subject to a detailed vesting schedule through monthly installments.

Were Robert Chess’s Twist Bioscience (TWST) transactions under a 10b5-1 plan?

Yes. The Form 4 states the transactions were effected under a Rule 10b5-1 trading plan that Robert Chess previously adopted on May 8, 2026, indicating they followed a pre-established trading program.

How many Twist Bioscience (TWST) shares are held through the Chess 1997 Trust?

After the reported transactions, 42,528 Twist Bioscience shares were held indirectly through the Chess 1997 Trust, for which Robert Chess and his spouse serve as the sole trustees and sole beneficiaries.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CHESS ROBERT

(Last)(First)(Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD.

(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/07/2026M(1)18,417A$11.8939,501D
Common Stock08/07/2026S(1)18,417D$110.8921,084D
Common Stock42,528IBy the Chess 1997 Trust(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$11.8908/07/2026M(1)18,417 (3)09/13/2028Common Stock18,417$00D
Explanation of Responses:
1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2026.
2. The Reporting Person and his spouse are the sole trustees and the sole beneficiaries of the Chess 1997 Trust.
3. The option is immediately exercisable. 10% of the shares subject to the option vested on September 13, 2018, 15% of the shares subject to the option vested on March 24, 2019, and 1/48th of the shares subject to the option vested on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
Remarks:
/s/ Kendra Fox, as Attorney-in-Fact for Robert Chess08/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)